ANIX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AN

Mkt Cap

$92.8M

Volume

114.78K

Loading chart

AN

ANIXAnixa Biosciences, Inc.

ANIX

Pay with—

Available Balance0.00

AN

Mkt Cap

$96.6M

Volume

114.78K

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine TechnologyAnixa Biosciences announced that the Mexican Institute of Industrial Property has issued Patent Number 432748 covering the company's breast cancer vaccine technology. The patent extends intellectual property protection into 2040 and strengthens Anixa's global patent portfolio. The vaccine, developed with Cleveland Clinic, targets human α-lactalbumin and showed positive Phase 1 results with 74% of participants eliciting protocol-defined immune responses. The company is preparing for Phase 2 clinical trials.Benzinga · Apr 29, 2026

Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine TechnologyAnixa Biosciences announced that South Korea's Ministry of Intellectual Property issued a Notice of Allowance for a patent covering the company's breast cancer vaccine technology. The patent, exclusively licensed from Cleveland Clinic, provides composition of matter protection in South Korea and expands Anixa's global intellectual property portfolio. The company's Phase 1 clinical trial showed the vaccine was safe, well-tolerated, and generated immune responses in 74% of participants.Benzinga · Mar 9, 2026

Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates ApprovalsThe cancer immunotherapy market is projected to reach $258.22 billion by 2031, driven by breakthrough treatments and FDA fast-track approvals. Multiple companies are developing innovative immunotherapies targeting various cancer types with promising clinical trial results.Benzinga · Sep 16, 2025

Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024Anixa Biosciences, a biotechnology company focused on cancer treatment and prevention, will present at the Sidoti Micro-Cap Virtual Conference on November 13-14, 2024. The company will provide updates on its breast cancer and ovarian cancer clinical trials, which have been producing positive results.Benzinga · Oct 31, 2024

EXCLUSIVE: FDA Approves Anixa Biosciences' Individual Patient Trial Application For Ovarian Cancer CAR-T Therapy - BenzingaThe FDA has approved Anixa Biosciences' application for an individual patient trial of its CAR-T therapy for recurrent ovarian cancer patients who have failed standard-of-care treatments. The therapy has shown promising early results, with one patient demonstrating a notable response despite initial tumor progression.Benzinga · Jul 23, 2024

Autonomix secures RF Innovations technology license By Investing.com - Investing.comAnixa Biosciences, a biotechnology company, has announced a $5 million stock buyback program, signaling confidence in its financial health and future prospects.Investing.com · Jul 15, 2024

Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne DrugDermata (DRMA) announces reaching an agreement with the FDA to begin a late-stage pivotal clinical program for its acne treatment candidate, DMT310. The stock rises 7%.Zacks Investment Research · Nov 17, 2023

Ardelyx (ARDX) Up on Xphozah's Orphan Tag for HyperphosphatemiaArdelyx (ARDX) announces that the FDA has granted orphan drug designation to Xphozah for the treatment of pediatric hyperphosphatemia. The stock rises 4%.Zacks Investment Research · Nov 17, 2023

Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline UpdatesKodiak (KOD) reports better-than-expected third-quarter 2023 results and provides updates regarding its pipeline development plans.Zacks Investment Research · Nov 15, 2023

Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin StudiesMoleculin (MBRX) announces positive interim data from its early-mid-stage studies of Annamycin in blood and lung cancer indications, along with encouraging third-quarter results. The stock rises 7%.Zacks Investment Research · Nov 14, 2023

to start trading

AN

ANIXAnixa Biosciences, Inc.

ANIX

Pay with—

Available Balance0.00

Your PositionYou don't own any ANIX yet.

Related Tickers

Earnings